Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Development and internal validation of the Laboratory-based Liver Frailty Index (Lab-LFI)-a prediction model for frailty in patients with cirrhosis.

Created on 24 Oct 2026

Authors

Michael Li, Catherine Lee, Nghiem B Ha, Srilakshmi Seetharaman, Chiung-Yu Huang, Jennifer C Lai

Published in

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. Oct 23, 2026. Epub Oct 23, 2026.

Abstract

Frailty, as measured by the Liver Frailty Index (LFI), is a well-established predictor of outcomes in cirrhosis, but testing requires in-person encounters. We sought to develop a blood-based biomarker index that correlates with frailty.
Seven serum/plasma analytes (myostatin, IL-6, growth differentiation factor-15 [GDF-15], testosterone, leucine-rich alpha-2 glycoprotein [LRG1], fetuin-A, and IGF-1) were measured by ELISA in 527 ambulatory cirrhosis patients. "Frail" was defined as LFI≥4.4. The cohort was split in half; the "Lab-LFI" was developed using LASSO regression in the training set and validated in the test set. Other machine learning methods (generalized additive model [GAM], Random Forest, and XGBOOST) were considered to compare discrimination. Of 527 patients (median age 59, MELD 14), 114 (21.6%) were frail. All seven biomarkers were associated with frailty. In the test set, Lab-LFI's c-statistic was 0.80 (95% CI 0.74-0.87) for frailty. The GAM, random forest, and XGBOOST approaches produced similar discrimination (c-statistics 0.79-0.82); as such, the LASSO model was chosen for maximum interpretability. Addition of clinical variables to the LASSO model, including MELD labs and sex, did not improve discrimination (c-statistic 0.79, 95% CI 0.72-0.85). Patients were stratified by Lab-LFI using a cutpoint maximizing Youden's index; after adjusting for MELD and liver disease etiology, the high-risk group had higher pre-transplant death/waitlist dropout (HR 1.77, 95% CI 1.17-2.68, p=0.007).
We developed and internally validated the Lab-LFI, a frailty prediction model consisting of 7 laboratory-based biomarkers. Lab-LFI enables blood-based assessment of physical function, as MELD does with liver function.

PMID:
42912651
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement